{"id":"NCT00141453","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial","officialTitle":"CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-04","primaryCompletion":"2008-08","completion":"2009-01","firstPosted":"2005-09-01","resultsPosted":"2011-05-10","lastUpdate":"2011-05-10"},"enrollment":577,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Nephropathy","Type 2 Diabetes Mellitus","Proteinuria"],"interventions":[{"type":"DRUG","name":"olmesartan medoxomil","otherNames":[]},{"type":"DRUG","name":"Placebo Tablets","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.","primaryOutcome":{"measure":"Renal Composite Outcomes","timeFrame":"Randomization to 5 years","effectByArm":[{"arm":"Olmesartan Medoxomil","deltaMin":116,"sd":null},{"arm":"Placebo Comparator","deltaMin":129,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.79"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":2,"countries":["China","Japan"]},"refs":{"pmids":["38682786","24013685","21993710"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":147,"n":287},"commonTop":["Nasopharyngitis","Oedema peripheral","Hypoglycaemia","Hyperkalaemia","Cough"]}}